Recombinant growth factors.
Recombinant human growth factors are expected to have a significant impact on the use of allogeneic blood components. For example, subsequent to the approval of recombinant human erythropoietin, blood transfusions in renal dialysis patients declined substantially. Likewise, myeloid growth factors have reduced infections and hospital stay by promoting hematologic recovery after high dose ablative chemotherapy. The high costs of these agents mandate that their use be limited to settings where they are clinically indicated. The use of growth factors may be monitored at medical centers by hospital transfusion committees. This chapter reviews the emerging clinical guidelines for the use of hematopoietic growth factors.
Goodnough
L T
LT
Washington University School of Medicine, St Louis, MO 63110, USA.
Anderson
K C
KC
D000328:Adult; D000740:Anemia / Q000628:therapy; D000818:Animals; D001855:Bone Marrow Diseases / Q000628:therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000235:genetics / Q000627:therapeutic use; D017408:Guidelines as Topic; D016298:Hematopoietic Cell Growth Factors / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use*; D007231:Infant, Newborn; D051379:Mice; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000627:therapeutic use*